CTRI/2023/04/051516尚未招募3 期
A Phase III, Randomized, Multi-centric, Double-blind, Double-dummy, Parallel-group, Prospective Study to Evaluate Efficacy and Safety of FDC of Acotiamide (As ER) 300 mg plus Pantoprazole 40 mg Capsule Compared to Monotherapy of Pantoprazole 40 mg tablet in patients with Refractory Gastroesophageal Reflux Disease (GERD) and Functional Dyspepsia - None
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male and female subjects between 18 to 65 years of age (both inclusive).
- •2. Patients with refractory GERD (erosive or non-erosive reflux disease confirmed by upper gastrointestinal endoscopy) i.e., those who have failed on conventional treatment. (Conventional treatment: Pantoprazole 40 mg tablet once daily for at least 8 weeks).
- •3. Subjects diagnostically confirmed of having Functional Dyspepsia (FD) with no evidence of gastric and duodenal organic abnormality by upper gastrointestinal endoscopy.
- •4. Patients who have experienced heartburn symptom on at least 2 of 7 days and regurgitation symptom on at least 1 of 7 days for at least 8 weeks prior to enrolment.
- •5. Female Subjects, of childbearing potential practicing an acceptable method of birth control such as sexual abstinence, intrauterine device IUD, a double-barrier method, condom plus spermicide, diaphragm plus spermicide, or vaginal spermicidal suppository; for the duration of the study as judged by the investigator(s)/study physician and agree to follow the same should be used during treatment. OR Postmenopausal for at least 1 year. OR Surgically sterile (bilateral tubal ligation/bilateral oophorectomy/ hysterectomy has been performed on the Subject).
- •6. Subjects who are able to understand and give voluntary, written informed consent to participate in this clinical investigation.
- •7. Subjects shall be willing, able to comply with the protocol requirements.
排除标准
- •1. Subjects using Proton Pump Inhibitor (PPI) other than pantoprazole.
- •2. Subjects planning to take an inhibitor of gastric acid secretion other than Pantoprazole, a prokinetic drug other than Acotiamide, or any herbal medicine for gastrointestinal disorders.
- •3. Subjects who had undergone total gastrectomy.
- •4. Subjects with symptoms of Irritable Bowel Disease (IBD).
- •5. Patients chronically ( > 5 doses on demand or for 3 consecutive days) using systemic corticosteroids or non-steroidal anti-inflammatory drugs including COX-2 inhibitors other than aspirin (less than or equal to 325 mg is allowed) within last 28 days prior to screening. Need for continuous anticoagulant therapy
- •6.Current or past history of:
- •- Patients with gastrointestinal hemorrhage, mechanical obstruction or perforation
- •- Atrophic gastritis or documented gastric malignancy or other GI malignancy
- •- History of active gastric or duodenal ulcers within 4 weeks prior to screening.
- •- Patients with Zollinger-Ellision syndrome or other hypersecretory condition
- •- GERD complications like Barretts oesophagus and/or definite dysplastic changes in the oesophagus.
- •- Pyloric stenosis, oesophageal stricture, Schatzkis ring, oesophageal or Gastroesophageal surgery and planned surgery during the study duration.
- •- History of hematemesis within last 2 months.
- •- Clinically significant conditions as per investigator discretion.
- •7. Subjects with history of liver, gallbladder, and pancreatic disorders.
- •8. Subjects confirmed positive for Helicobacter pylori by the rapid urease test.
- •9. Subjects with abnormal eGFR ( < 60 mL/min/1.73 m2) will be excluded from the study.
- •10. Subjects with abnormal Liver Function Test (AST & ALT) with values more than 2.5 times the upper limit of normal.
- •11. Subjects with known case of Oncological Conditions.
- •12. Subjects with known history of infection with HIV, Hepatitis B virus or Hepatitis C virus.
- •13. Subject with any clinically significant laboratory abnormalities at screening as per investigator discretion.
- •14. Subjects with any other medical condition that might adversely impact the safety of the study participants or confound the study results.
- •15. Suspected hypersensitivity to Pantoprazole or Acotiamide or any of the ingredients of the formulation.
- •16. Female subjects who are pregnant or lactating or planning to become pregnant during the study period.
- •17. Female subjects who are not ready to use acceptable contraceptive methods during the course of study.
- •18. Female subjects with positive urine pregnancy test at screening.
- •19. Subjects with drug abuse or having any condition that would compromise compliance with this protocol.
- •20. Subjects who have been treated with an investigational drug or investigational device within a period of 4 weeks prior to study entry.
- •21. Currently taking prohibited concomitant medication(s) listed and inability/unwillingness to discontinue them for the entire study period.
- •22. Suspected inability or unwillingness to comply with the study procedures
研究者
相似试验
已完成
3 期
clinical trail (Phase III)of Fixed Dose Combination of Pregabalin and DuloxetineCapsuleCTRI/2020/09/027555Torrent Pharmaceuticals Limited328
进行中（未招募）
不适用
A phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine SystemTravelers' DiarrheaMedDRA version: 13.1Level: LLTClassification code 10044552Term: Traveller's diarrheaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-008726-75-DEIntercell USA, Inc. (Intercell)2,400
进行中（未招募）
不适用
A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers’ Diarrhea Vaccine SystemTravelers' DiarrheaMedDRA version: 9.1Level: LLTClassification code 10044552Term: Traveller's diarrheaEUCTR2008-008726-75-GBIntercell USA, Inc. (Intercell)2,400
尚未招募
3 期
A Phase III multicentric prospective comparative clinical trial to evaluate efficacy and safety of LifeViroTreat inhalation in mild nCOVID-19 infected patientCTRI/2022/03/041214Supreme Drugs Pvt Ltd
已完成
3 期
CALLAJPRN-jRCT2080224829AstraZeneca KK72